Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
GLP-1 Agonist Semaglutide Brand names: Ozempic (diabetes) Wegovy (weight loss) 1517% Average body weight reduction (STEP trials) Activates GLP-1 receptors in gut and brain Suppresses appetite, slows gastric emptying Regulates blood sugar and insulin response Weekly subcutaneous injection or daily oral (Rybelsus) Cardiovascular outcome data: SELECT trial (2023) Dual GLP-1 + GIP Agonist Tirzepatide Brand names: Mounjaro (diabetes) Zepbound (weight loss) 2022% Average body weight reduction (SURMOUNT trials) Activates both GLP-1 AND GIP receptors Stronger effect on insulin sensitivity than semaglutide alone Greater fat loss, especially visceral fat Weekly subcutaneous injection only Head-to-head vs semaglutide: SURPASS-6 favors tirzepatide The core difference is the receptor target
Examples such as Libbs Farmacutica, source both the API and key starting material from Sinopep in China, highlighting once again the central role of China in peptide manufacturing
These findings are valuable for mechanism, but they cannot substitute for controlled human outcomes
While FDA-guidelines are critical for understanding GLP-1 eligibility, there are a number of other factors to consider for determining GLP-1 eligibility
